Literature DB >> 20721916

Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain).

Javier Ruiz-Martínez1, Ana Gorostidi, Berta Ibañez, Ainhoa Alzualde, David Otaegui, Fermin Moreno, Adolfo López de Munain, Alberto Bergareche, Juan Carlos Gómez-Esteban, José F Martí Massó.   

Abstract

The LRRK2 R1441G mutation was first identified in Basque families and it is responsible for 46% of familial Parkinson's disease (PD) and for 2.5% of sporadic PD in the PD population of Basque ascent. The aim of this study was to determine LRRK2 R1441G penetrance in PD in the Basque Country (Spain) to help in a more accurate genetic counseling. A total of 59 sibships containing 244 individuals, with a total of 40 PD-affected relatives, were studied. Genetic testing for the R1441G mutation in the LRRK2 gene was performed in 133 individuals and was positive in 51% of them. Lifetime penetrance of R1441G mutations turned out to be 12.5% at 65 years to 83.4% at 80 years. No gender differences were found in penetrance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20721916     DOI: 10.1002/mds.23278

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  14 in total

1.  Gender differences in the risk of familial parkinsonism: beyond LRRK2?

Authors:  R Saunders-Pullman; K Stanley; M San Luciano; M J Barrett; V Shanker; D Raymond; L J Ozelius; S B Bressman
Journal:  Neurosci Lett       Date:  2011-04-12       Impact factor: 3.046

Review 2.  LRRK2 in Parkinson disease: challenges of clinical trials.

Authors:  Eduardo Tolosa; Miquel Vila; Christine Klein; Olivier Rascol
Journal:  Nat Rev Neurol       Date:  2020-01-24       Impact factor: 42.937

Review 3.  Role of LRRK2 kinase dysfunction in Parkinson disease.

Authors:  Azad Kumar; Mark R Cookson
Journal:  Expert Rev Mol Med       Date:  2011-06-13       Impact factor: 5.600

4.  Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.

Authors:  Lorraine V Kalia; Anthony E Lang; Lili-Naz Hazrati; Shinsuke Fujioka; Zbigniew K Wszolek; Dennis W Dickson; Owen A Ross; Vivianna M Van Deerlin; John Q Trojanowski; Howard I Hurtig; Roy N Alcalay; Karen S Marder; Lorraine N Clark; Carles Gaig; Eduardo Tolosa; Javier Ruiz-Martínez; Jose F Marti-Masso; Isidre Ferrer; Adolfo López de Munain; Samuel M Goldman; Birgitt Schüle; J William Langston; Jan O Aasly; Maria T Giordana; Vincenzo Bonifati; Andreas Puschmann; Margherita Canesi; Gianni Pezzoli; Andre Maues De Paula; Kazuko Hasegawa; Charles Duyckaerts; Alexis Brice; A Jon Stoessl; Connie Marras
Journal:  JAMA Neurol       Date:  2015-01       Impact factor: 18.302

Review 5.  The role of monogenic genes in idiopathic Parkinson's disease.

Authors:  Xylena Reed; Sara Bandrés-Ciga; Cornelis Blauwendraat; Mark R Cookson
Journal:  Neurobiol Dis       Date:  2018-11-15       Impact factor: 5.996

Review 6.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

Review 7.  Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications.

Authors:  Zhenyu Yue; M Lenard Lachenmayer
Journal:  Mov Disord       Date:  2011-04-29       Impact factor: 10.338

8.  The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot.

Authors:  Ignacio F Mata; Marie Y Davis; Alexis N Lopez; Michael O Dorschner; Erica Martinez; Dora Yearout; Brenna A Cholerton; Shu-Ching Hu; Karen L Edwards; Thomas D Bird; Cyrus P Zabetian
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2016-04-25       Impact factor: 3.568

Review 9.  Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells.

Authors:  Liesel Goveas; Eugénie Mutez; Marie-Christine Chartier-Harlin; Jean-Marc Taymans
Journal:  Cells       Date:  2021-04-22       Impact factor: 6.600

10.  Epitope Mapping of Antibodies to Alpha-Synuclein in LRRK2 Mutation Carriers, Idiopathic Parkinson Disease Patients, and Healthy Controls.

Authors:  Beatriz Alvarez-Castelao; Ana Gorostidi; Javier Ruíz-Martínez; Adolfo López de Munain; José G Castaño
Journal:  Front Aging Neurosci       Date:  2014-07-15       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.